Grifols, S.a. Share Price Today
(NASDAQ: GRFS)

Name: Grifols, S.a. Share Price Today (NASDAQ: GRFS) - Grifols, S.a. Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Grifols, S.a. share price is $6.91 & ₹598.35 as on 31 Jan 2025, 2.30 'hrs' IST

$6.91

▲

-0.09

(-1.29%)

Market is closed - opens 8 PM, 31 Jan 2025

View live Grifols, S.a. share price in Dollar and Rupees. Guide to invest in Grifols, S.a. stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Grifols, S.a., along with analyst recommendations, forecasts, and comprehensive financials.

Grifols, S.a. share price movements

Today's Low: $6.91
Today's High: $7.03
$6.91
0.0%
Downside
Day's Volatility :1.64%
Upside
1.64%
52 Weeks Low: $5.30
52 Weeks High: $9.96
$6.91
23.3%
Downside
52 Weeks Volatility :46.79%
Upside
30.62%

Grifols, S.a. (GRFS) Returns

Period	Grifols, S.a.	Sector (Health Care)	Index (Russel 2000)
3 Months	-20.81%	-1.7%	0.0%
6 Months	-7.65%	-3.0%	0.0%
1 Year	-12.83%	3.6%	0.0%
3 Years	-41.76%	11.6%	-10.1%

Grifols, S.a. (GRFS) Key Statistics

in dollars & INR

Previous Close	$7.0
Open	$7.05
Today's High	$7.025
Today's Low	$6.91
Market Capitalization	$7.1B
Today's Volume	$727.2K
52 Week High	$9.96
52 Week Low	$5.3001
Revenue TTM	$7.0B
EBITDA	$1.3B
Earnings Per Share (EPS)	$0.26
PE Ratio	35.0
Profit Margin	2.31%
Quarterly Earnings Growth YOY	-0.67%
Return On Equity TTM	2.71%

How to invest in Grifols, S.a. Stock (GRFS) from India?

It is very easy for Indian residents to invest directly in Grifols, S.a. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Grifols, S.a. stock in both Indian Rupees (INR) and US Dollars (USD). Search for Grifols, S.a. or GRFS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Grifols, S.a. or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Grifols, S.a. shares which would translate to 0.125 fractional shares of Grifols, S.a. as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Grifols, S.a., in just a few clicks!

Returns in Grifols, S.a. (GRFS) for Indian investors in Rupees

The Grifols, S.a. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Grifols, S.a. investment value today

Current value as on today

₹90,343

Returns

₹9,657

(-9.66%)

Returns from Grifols, S.a. Stock

₹13,948 (-13.95%)

Dollar Returns

₹4,291 (+4.29%)

Indian investors sentiment towards Grifols, S.a. (GRFS)

-44%

Period: Dec 31, 2025 to Jan 30, 2025. Change in 30 Days versus previous period

Search interest for Grifols, S.a. Stock from India on INDmoney has decreased by -44% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Grifols, S.a.

Capital World Investors
3.09%
Brandes Investment Partners & Co
2.93%
Permian Investment Partners
1.81%
Black Creek Investment Management Inc
1.63%
Millennium Management LLC
1.58%
Armistice Capital, LLC
1.40%

Analyst Recommendation on Grifols, S.a.

Buy

63%Buy

22%Hold

13%Sell

Based on 22 Wall street analysts offering stock ratings for Grifols, S.a.(by analysts ranked 0 to 5 stars)

Based on 22 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Grifols, S.a. Stock (GRFS)

What analysts predicted

Upside of 54.41%

Target:

$10.67

Current:

$6.91

Insights on Grifols, S.a. Stock (Ticker Symbol: GRFS)

Price Movement
In the last 7 days, GRFS stock has moved down by -6.3%
Decreasing Revenue
Revenue is down for the last 2 quarters, 1.81B → 1.79B (in $), with an average decrease of 1.4% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 14.84M → 51.69M (in $), with an average increase of 71.3% per quarter
GRFS vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 24.7% return, outperforming this stock by 39.9%
GRFS vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 228.1% return, outperforming this stock by 268.2%
Price to Sales
ForGRFS every $1 of sales, investors are willing to pay $1.4, whereas for Eli Lilly And Company, the investors are paying $17.7 for every $1 of sales.

GRFS Grifols, S.a. Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$4.5B	↑ 3.91%
Net Income	$596.6M	↓ 9.97%
Net Profit Margin	13.3%	↓ 2.05%

	FY19	Y/Y Change
Revenue	$5.1B	↑ 13.64%
Net Income	$625.1M	↑ 4.78%
Net Profit Margin	12.26%	↓ 1.04%

	FY20	Y/Y Change
Revenue	$5.3B	↑ 4.73%
Net Income	$618.5M	↓ 1.06%
Net Profit Margin	11.58%	↓ 0.68%

	FY21	Y/Y Change
Revenue	$5.6B	↓ 7.62%
Net Income	$299.9M	↓ 57.1%
Net Profit Margin	5.38%	↓ 6.2%

	FY22	Y/Y Change
Revenue	$6.4B	↑ 22.92%
Net Income	$220.4M	↓ 21.5%
Net Profit Margin	3.43%	↓ 1.95%

	FY23	Y/Y Change
Revenue	$7.2B	↑ 8.71%
Net Income	$64.7M	↓ 71.52%
Net Profit Margin	0.9%	↓ 2.53%

	Q2 FY23	Q/Q Change
Revenue	$1.8B	↓ 2.88%
Net Income	$65.1M	↑ 199.13%
Net Profit Margin	3.61%	↑ 2.44%

	Q3 FY23	Q/Q Change
Revenue	$1.7B	↓ 3.97%
Net Income	$63.6M	↓ 0.82%
Net Profit Margin	3.73%	↑ 0.12%

	Q4 FY23	Q/Q Change
Revenue	$1.9B	↑ 10.77%
Net Income	$61.1M	↓ 5.96%
Net Profit Margin	3.16%	↓ 0.57%

	Q1 FY24	Q/Q Change
Revenue	$1.6B	↓ 8.13%
Net Income	$21.4M	↓ 61.75%
Net Profit Margin	1.32%	↓ 1.84%

	Q2 FY24	Q/Q Change
Revenue	$2.0B	↑ 11.82%
Net Income	$16.0M	↓ 30.71%
Net Profit Margin	0.82%	↓ 0.5%

	Q3 FY24	Q/Q Change
Revenue	$1.8B	↓ 1.37%
Net Income	$51.7M	↑ 248.3%
Net Profit Margin	2.88%	↑ 2.06%

	FY18	Y/Y Change
Profit	$2.0B	↓ 4.76%

	FY19	Y/Y Change
Profit	$2.3B	↑ 14.23%

	FY20	Y/Y Change
Profit	$2.3B	↓ 3.68%

	FY21	Y/Y Change
Profit	$2.2B	↓ 12.97%

	FY22	Y/Y Change
Profit	$2.4B	↑ 13.7%

	FY23	Y/Y Change
Profit	$2.5B	↑ 4.09%

	Q2 FY23	Q/Q Change
Profit	$672.6M	↑ 3.5%

	Q3 FY23	Q/Q Change
Profit	$674.5M	↑ 1.9%

	Q4 FY23	Q/Q Change
Profit	$752.5M	↑ 9.18%

	Q1 FY24	Q/Q Change
Profit	$648.4M	↓ 6.0%

	Q2 FY24	Q/Q Change
Profit	$668.0M	↓ 4.26%

	Q3 FY24	Q/Q Change
Profit	$726.8M	↑ 17.07%

	FY18	Y/Y Change
Operating Cash Flow	$737.4M	↓ 12.39%
Investing Cash Flow	$-781.9M	↓ 64.23%
Financing Cash Flow	$152.5M	↓ 89.37%

	FY19	Y/Y Change
Operating Cash Flow	$568.9M	↓ 22.85%
Investing Cash Flow	$-548.8M	↓ 29.81%
Financing Cash Flow	$-332.4M	↓ 317.93%

	FY20	Y/Y Change
Operating Cash Flow	$1.1B	↑ 95.16%
Investing Cash Flow	$-858.1M	↑ 56.37%
Financing Cash Flow	$-354.4M	↑ 6.63%

	FY21	Y/Y Change
Operating Cash Flow	$674.9M	↓ 46.23%
Investing Cash Flow	$-33.2M	↓ 96.57%
Financing Cash Flow	$1.7B	↓ 515.61%

	FY22	Y/Y Change
Operating Cash Flow	$-11.5M	↓ 101.82%
Investing Cash Flow	$-2.1B	↑ 6632.29%
Financing Cash Flow	$-183.6M	↓ 111.78%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-45.9M	↓ 162.65%
Investing Cash Flow	$-133.3M	↑ 0.0%
Financing Cash Flow	$206.0M	↓ 6.07%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$166.1M	↓ 468.16%
Investing Cash Flow	$-131.2M	↑ 0.0%
Financing Cash Flow	$-84.7M	↓ 141.79%

Grifols, S.a. Technicals Summary

Sell

Neutral

Buy

Grifols, S.a. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Grifols, S.a. (GRFS) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Grifols, S.a.	-7.16%	-7.65%	-12.83%	-41.76%	-69.47%
Eli Lilly And Company	4.16%	-0.05%	21.75%	223.86%	470.27%
Johnson & Johnson	4.52%	-7.91%	-4.55%	-11.55%	0.65%
Merck & Co. Inc.	-0.9%	-14.69%	-22.23%	19.97%	12.53%
Novo Nordisk A/s	-2.31%	-34.09%	-27.43%	63.8%	175.69%
Abbvie Inc	-2.33%	-7.41%	4.58%	27.93%	112.95%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Grifols, S.a.	35.0	35.0	0.23	0.68	0.03	0.03	NA	7.87
Eli Lilly And Company	86.83	86.83	0.76	12.93	0.65	0.14	0.01	15.83
Johnson & Johnson	25.97	25.97	0.97	10.55	0.21	0.08	0.03	29.14
Merck & Co. Inc.	20.39	20.39	0.07	7.67	0.28	0.11	0.03	17.58
Novo Nordisk A/s	28.78	28.78	1.45	22.15	0.89	0.21	0.02	27.07
Abbvie Inc	60.91	60.91	0.42	10.48	0.56	0.08	0.04	3.41

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Grifols, S.a.	Buy	$7.1B	-69.47%	35.0	2.31%
Eli Lilly And Company	Buy	$723.1B	470.27%	86.83	20.48%
Johnson & Johnson	Buy	$362.1B	0.65%	25.97	16.74%
Merck & Co. Inc.	Buy	$246.5B	12.53%	20.39	19.23%
Novo Nordisk A/s	Buy	$379.5B	175.69%	28.78	35.01%
Abbvie Inc	Buy	$308.9B	112.95%	60.91	9.22%

Grifols, S.a. Dividend announcements

Grifols, S.a. Dividends June, 2021
In the quarter ending June,2021. Grifols, S.a. has declared dividend of $0.46
Read More

About Grifols, S.a.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Organization	Grifols, S.a.
Employees	23000
CEO	Mr. Jose Ignacio Abia Buenache
Industry	Health Technology

Management People of Grifols, S.a.

Name	Title
Mr. Jose Ignacio Abia Buenache	CEO & Director
Mr. Alfredo Arroyo Guerra CPA	CFO & VP
Mr. Lluis Pons Gomez	Senior Vice President of Strategy & COO Office
Ms. Nuria Pascual Lapeña	VP of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer
Mr. David Ian Bell	Chief Corporate Development, Legal & Data Protection Officer
Ms. Maria Teresa-Rioné Llano	Chief Communications Officer
Mr. Camille Alpi	Chief Human Resources & Talent Officer
Mr. Vicente Blanquer Torre	Chief Quality Officer
Mr. Sergio Roura Adell	President of Commercial Tech Support
Mr. Víctor Grifols Deu	Executive Director

Important FAQs about investing in GRFS Stock from India :

What is Grifols, S.a. share price today?

Grifols, S.a. share price today stands at $6.91, Open: $7.05 ; Previous Close: $7.00 ; High: $7.03 ; Low: $6.91 ; 52 Week High: $9.96 ; 52 Week Low: $5.30.

The stock opens at $7.05, after a previous close of $7.00. The stock reached a daily high of $7.03 and a low of $6.91, with a 52-week high of $9.96 and a 52-week low of $5.30.

Can Indians buy Grifols, S.a. shares?

Yes, Indians can invest in the Grifols, S.a. (GRFS) from India.

With INDmoney, you can buy Grifols, S.a. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Grifols, S.a. at zero transaction cost.

How can I buy Grifols, S.a. shares from India?

It is very easy to buy Grifols, S.a. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Grifols, S.a. (GRFS) be purchased?

Yes, you can buy fractional shares of Grifols, S.a. with INDmoney app.

What are the documents required to start investing in Grifols, S.a. stocks?

To start investing in Grifols, S.a., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.